Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 for Immune Reconstitution in Older Cancer Survivors
NCT04054752Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efineptakin alfa in breast carcinoma, colorectal adenocarcinoma and bladder carcinoma (3 arms), sponsored by National Cancer Institute. Primary endpoints: Safety of NT-I7 in elderly patients after chemotherapy at 28 days, Impact of NT-I7 on specific immune responses to vaccines at Day 106 and 1 more. Planned start May 2023; status: withdrawn.
02
Drugs
efineptakin alfa
03
Conditions
breast carcinomacolorectal adenocarcinomabladder carcinoma
Beyond the preview
Go deeper on NCT04054752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054752.